Skip to main content
Premium Trial:

Request an Annual Quote

Tecan, JPT to Co-promote Array Products

NEW YORK (GenomeWeb News) – Tecan and JPT Peptide Technologies today announced a deal to co-promote JPT's catalog peptide arrays and profiling capabilities.

Under the terms of the agreement, the companies will co-promote JPT's products alongside Tecan's microarray handling devices. Other terms were not disclosed.

"Providing a high level of data quality and consistency is a burning need in microarray research," Siegfried Sasshofer, director of marketing detection at Tecan Austria, said in a statement. "Combining JPT peptide microarrays with our Tecan HS 4800 Pro and HS 400 Pro hybridization stations for automated microarray processing will provide our customers with a new level of process standardization to maximize the value of their research."

Tecan, based in Männedorf, Switzerland, provides laboratory instruments and solutions to the biopharmaceutical, forensics, and clinical diagnostics markets. Based in Berlin, JPT is a wholly owned subsidiary of BioNTech and provides services and tools for peptide-related projects.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.